Announcement Regarding Listing Rule 6.1.19R

RNS Number : 1554B

PureTech Health PLC

05 October 2015

 



05 October 2015

PureTech Health plc

Announcement Regarding Listing Rule 6.1.19R

PureTech Health plc ("PureTech" or the "Company") is subject to the requirements of Listing Rule 6.1.19R. Under Listing Rule 6.1.19R, shares held outside of the EEA states or by persons in the same group acting in concert who have an interest in 5% or more of a listed company's share capital, as well as shares held by directors of a listed company (and shares held by directors of subsidiary undertakings of a listed company) are not regarded as being held in public hands (the "free float"). The minimum free float requirement for premium listed companies is 25%.

PureTech has recently initiated dialogue with the UK Listing Authority ("UKLA") of the Financial Conduct Authority regarding the Company's free float and, at the Company's request, the UKLA has granted PureTech a modification to Listing Rule 6.1.19R to allow shares outside of the EEA (including the US, Canada, and Switzerland) in addition to shares held in EEA States to be included within the definition of the free float as it applies to the Company.  

Based on analysis of its latest available shareholder register and notifications of significant shareholdings received to date, the Company estimates that its free float, under the Listing Rule 6.1.19R definition, and taking into account the modification to allow inclusion of shares held outside of the EEA, is above 40%.

For further information please contact:

PureTech
Julie DiCarlo, Senior Vice President, Communications and Investor Relations	[phone]
FTI Consulting (Communications adviser to PureTech) Ben Atwell / Matthew Cole	[phone]

About PureTech

PureTech (PureTech Health plc, PRTC.L) is a cross-disciplinary healthcare company, developing innovative products that could improve the lives of billions of patients. PureTech has a pipeline of 12 operating companies, seven of which are "growth stage" with external validation including strategic partnerships, outside funding, proof-of-concept or peer review in prestigious scientific journals. PureTech also has a pipeline of ten "concept phase" initiatives resulting from review of more than 650 ideas annually. PureTech is focused on areas including, immune and inflammatory disorders; cognitive and psychiatric disorders; diabetes and obesity; oncology; and infectious diseases, and has over 110 patents and patent applications. PureTech's leading team and board, along with an advisory network of more than 50 expert founder-scientists and advisors across multiple disciplines, gives PureTech access to potentially ground-breaking science and technological innovation. For more information, visit www.puretechhealth.com and connect with us on Twitter.

###

 

END

 

 

MSCPKQDQNBDDOKK